Home/Filings/4/0001140361-19-019741
4//SEC Filing

KKR Associates HCSG L.P. 4

Accession 0001140361-19-019741

CIK 0001720725other

Filed

Nov 3, 7:00 PM ET

Accepted

Nov 4, 6:19 PM ET

Size

15.6 KB

Accession

0001140361-19-019741

Insider Transaction Report

Form 4
Period: 2019-11-04
Transactions
  • Purchase

    Common Stock, par value $0.001 per share

    2019-11-04$16.00/sh+155,000$2,480,0001,039,622 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2019-11-04884,6220 total(indirect: See footnotes)
    Common Stock, par value $0.001 per share (884,622 underlying)
  • Conversion

    Common Stock, par value $0.001 per share

    2019-11-04+884,622884,622 total(indirect: See footnotes)
Transactions
  • Conversion

    Common Stock, par value $0.001 per share

    2019-11-04+884,622884,622 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2019-11-04884,6220 total(indirect: See footnotes)
    Common Stock, par value $0.001 per share (884,622 underlying)
  • Purchase

    Common Stock, par value $0.001 per share

    2019-11-04$16.00/sh+155,000$2,480,0001,039,622 total(indirect: See footnotes)
Transactions
  • Purchase

    Common Stock, par value $0.001 per share

    2019-11-04$16.00/sh+155,000$2,480,0001,039,622 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2019-11-04884,6220 total(indirect: See footnotes)
    Common Stock, par value $0.001 per share (884,622 underlying)
  • Conversion

    Common Stock, par value $0.001 per share

    2019-11-04+884,622884,622 total(indirect: See footnotes)
Transactions
  • Conversion

    Common Stock, par value $0.001 per share

    2019-11-04+884,622884,622 total(indirect: See footnotes)
  • Purchase

    Common Stock, par value $0.001 per share

    2019-11-04$16.00/sh+155,000$2,480,0001,039,622 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2019-11-04884,6220 total(indirect: See footnotes)
    Common Stock, par value $0.001 per share (884,622 underlying)
Footnotes (3)
  • [F1]These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock, on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering.
  • [F2]The securities reported herein are held by Falcon Vision LLC. KKR Health Care Strategic Growth Fund L.P., as the managing member of Falcon Vision LLC, KKR Associates HCSG L.P., as the general partner of KKR Health Care Strategic Growth Fund L.P., KKR HCSG GP LLC, as the general partner of KKR Associates HCSG L.P., KKR Fund Holdings L.P., as the sole member of KKR HCSG GP LLC, KKR Fund Holdings GP Limited, as a general partner of KKR Fund Holdings L.P., KKR Group Holdings Corp., as a general partner of KKR Fund Holdings L.P. and the sole shareholder of KKR Fund Holdings GP Limited, KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described in this footnote.
  • [F3]Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by Falcon Vision LLC.

Issuer

Oyster Point Pharma, Inc.

CIK 0001720725

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001792766

Filing Metadata

Form type
4
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 6:19 PM ET
Size
15.6 KB